Gilead to buy Kite for promising cancer therapies in $12 billion deal: Reuters

Gilead Sciences Inc agreed to buy Kite Pharma Inc in a $11.9 billion deal on Monday, as it looks to fuel growth with an emerging class of cancer immunotherapies that are expected to generate billions, Reuters reported.

DealsNorth AmericaUSBriefs